Why is a deep value investor bearish on Eli Lilly at $1,036/share? My analysis finds the $800B valuation fails to account for structural pricing pressure, competitive threats, and regulatory risks facing weight-loss drugs. https://post.kapualabs.com/3e5jfdrv #ValueInvesting #StockAnalysis #Pharma